Prokidney CORP

ProKidney Corp. stockholders re-elected three directors and ratified the appointment of Ernst & Young LLP as the independent auditor for 2026.

ProKidney Corp. announced its first quarter 2026 financial results, highlighting progress in its Phase 3 PROACT 1 study for chronic kidney disease and maintaining a cash runway into mid-2027.

ProKidney Corp. announced its full year 2025 financial results, highlighting progress in its Phase 3 PROACT 1 study for rilparencel and confirming FDA alignment on an accelerated approval pathway.

ProKidney Corp. updated its investor presentation, highlighting positive Phase 2 data, FDA alignment on an accelerated approval pathway for rilparencel, and progress in its pivotal Phase 3 PROACT 1 study with topline results expected in Q2 2027.

ProKidney Corp. reported its third-quarter 2025 financial results, highlighting positive Phase 2 clinical data for rilparencel and FDA alignment on an accelerated approval pathway for its Phase 3 study, with cash reserves projected into mid-2027.

ProKidney Corp. has entered into a new definitive agreement to sell its Greensboro, North Carolina property to Northpoint Development, LLC for approximately $19.1 million in cash.

ProKidney Corp. reported a net loss of $20.0 million for the first quarter of 2026, with research and development expenses increasing significantly due to ongoing Phase 3 clinical trials.

ProKidney Corp. announced its third-quarter 2025 financial results, highlighting positive Phase 2 trial data for rilparencel and FDA alignment on its Phase 3 accelerated approval pathway, despite continued net losses and a need for future funding.

ProKidney reports positive Phase 2 trial results for rilparencel and secures FDA clarity for its pivotal Phase 3 study, extending cash runway into mid-2027.

ProKidney Corp. announces its Q1 2025 financial results, highlighting a refined clinical trial strategy focusing on the PROACT 1 trial for potential accelerated FDA approval of rilparencel.

ProKidney Corp. reports its financial results for the third quarter of 2024, including a net loss, and provides an update on its clinical trial strategy for rilparencel.

ProKidney Corp. released its second quarter 2024 financial results, highlighting progress in clinical trials and a recent capital raise.

ProKidney Corp.'s 2024 10-K filing reveals ongoing net losses as the company advances its rilparencel clinical development program for chronic kidney disease.

ProKidney Corp.'s 10-K filing details the terms of its Class A and Class B ordinary shares, as well as preference shares, and includes information on voting rights, dividend rights, transfer of shares, and liquidation procedures.

ProKidney Corp. reports the grant of employee stock options to Chief Technical Officer Kenneth Thomas Locke.

Chief Legal Officer Todd C. Girolamo converted 163,857 shares of Class B Common Stock and paired units into Class A Common Stock.

Director Alan Lotvin was granted 135,000 stock options under ProKidney Corp.'s non-employee director compensation policy.

Director Jose Ignacio Jimenez Santos was granted 135,000 stock options as part of ProKidney Corp.'s non-employee director compensation policy.

Director Jennifer A. Fox was granted 135,000 stock options in ProKidney Corp as part of the company's non-employee director compensation policy.

Director William F. Doyle was granted 135,000 stock options in ProKidney Corp. as part of the company's non-employee director compensation policy.

ProKidney Corp. has issued its proxy statement for the 2026 annual meeting of stockholders to be held on May 28, 2026.

ProKidney Corp. announces its 2024 annual general meeting to be held on May 30, 2024, featuring the election of directors and ratification of the company's independent auditor.

The Slim family and Control Empresarial have increased their beneficial ownership in ProKidney Corp. to 36% following a share exchange.

Tolerantia, LLC and its controlling person, Pablo Legorreta, continue to beneficially own 36.5% of ProKidney Corp.'s combined Class A and Class B ordinary shares after a recent distribution of Class A shares to unaffiliated investors.

Tolerantia, LLC and Pablo G. Legorreta have filed an Amendment No. 4 to their Schedule 13D, detailing a recent internal share exchange and reaffirming their significant beneficial ownership of 38% in ProKidney Corp.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have reported a 6.0% beneficial ownership stake in PROKIDNEY CORP.'s Class A Common Stock.

Morgan Stanley and its investment management arm have reduced their beneficial ownership in PROKIDNEY CORP. to below the 5% reporting threshold.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 1.4% of PROKIDNEY CORP's Class A Stock as of June 30, 2025.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have disclosed a 7.8% beneficial ownership stake in PROKIDNEY CORP. as of March 31, 2025, according to an amended Schedule 13G filing.